Home/NeOnc Technologies/Steven L. Giannotta
SL

Steven L. Giannotta

Board Director and Scientific Advisory Board Member

NeOnc Technologies

NeOnc Technologies Pipeline

DrugIndicationPhase
NEO100Recurrent High-Grade Glioma (e.g., Glioblastoma)Phase 2
NEO212Primary & Recurrent Malignant Glioma, Brain MetastasesPhase 1/2
NEO400UV-Induced Skin DamagePreclinical